BRUSSELS, March 13 (Reuters) - U.S. medical equipment supplier Becton Dickinson & Co gained European Union approval on Friday for its $12.2 billon bid for peer CareFusion Corp after regulators said...
CareFusion posted impressive second-quarter results ..... Healthcare’s Vital Signs segment, CareFusion continues to benefit from operating ..... continue to expand for the firm. All of CareFusion ’s product lines also posted impressive
neutral basis, we're maintaining our fair value estimate. Our moat rating is unchanged, but we note that the acquisition of Carefusion could be moat-enhancing over the long run. Total organic revenue growth came in at 5.3% on a currency-neutral basis
Hillshire and Becton Dickinson 's BDX attempt to acquire CareFusion CFN . Juliet Ellis, Juan Hartsfield, and Clay Manley ..... discretionary and health care have helped, including CareFusion , Whitewave Foods WWAV, and Marriott MAR. The fund
tech acquisition. While not perfect comps, recent deals in the med tech space, such as Becton Dickinson's acquisition of Carefusion for 3.1 times sales and Zimmer's purchase of Biomet for 4.2 times sales, provide some support to this deal. The Volcano
CareFusion ’s fiscal first-quarter results of ..... Becton Dickinson for next year. We think CareFusion remains on track for roughly mid-single ..... Dickinson’s global presence, something CareFusion has struggled to build on its own.
community last month with its acquisition of CareFusion , its fourth-quarter and year-end ..... markets. This will change once the CareFusion deal closes, given that firm's lower ..... emerging-markets infrastructure to expand CareFusion 's presence particularly in China
10% TOP HOLDINGS Name % of Fund JPMorgan US Government Money Market Fund;Capital 1.40 Lincoln National Corp 1.10 CareFusion Corp 0.96 Allstate Corp 0.90 Computer Sciences Corp 0.90 Brunswick Corp 0.88 Ashland Inc 0.83 PG&E Corp 0.72
this past weekend that it is acquiring Carefusion for $12.2 billion in cash and stock ..... despite a rather rich multiple paid for Carefusion shares. We believe strategic revenue ..... should benefit from the inclusion of CareFusion . Further product diversification bodes
A swift turnaround in medical systems revenue led CareFusion to slightly outperform our year-end forecast. The company ..... incrementally benefit the company's narrow economic moat. CareFusion posted impressive 24% revenue growth during the fourth